| In millions, except per share items | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| China | 152.6 | 151.6 | 130.3 | 122.6 | 152.2 | 128.9 | 82.0 | 69.7 |
| Rest of the World (including the US) | | | | | | | 3.1 | 2.7 |
| Rest of the World (including the US and Hong Kong) | | | | 4.4 | | 3.6 | | |
| Sanofi | | | | | | 19.7 | | |
| Other | 7.5 | 5.7 | 4.5 | | 4.0 | | | |
| Total revenues [+] | 160.1 | 157.3 | 134.8 | 127.1 | 156.3 | 132.6 | 85.1 | 72.4 |
| Royalties | | | | | | 12.3 | 12.4 | 16.5 |
| Products | 155.9 | 154.3 | 132.0 | 99.4 | 123.2 | 112.0 | 85.1 | 72.4 |
| Revenue growth [+] | 1.8% | 16.7% | 6.1% | -18.7% | 17.9% | 55.8% | 17.5% | 33.8% |
| China | 0.7% | 16.3% | 6.3% | -19.5% | 18.1% | 57.2% | 17.7% | |
| Rest of the World (including the US) | | | | | | | 14.2% | |
| Cost of goods sold | 22.9 | 22.3 | 23.0 | 17.7 | 149.9 | 19.4 | 62.7 | 59.8 |
| Gross profit | 137.2 | 134.9 | 111.8 | 109.4 | 6.4 | 113.2 | 22.4 | 12.6 |
| Gross margin | 85.7% | 85.8% | 82.9% | 86.1% | 4.1% | 85.4% | 26.3% | 17.4% |
| Selling, general and administrative [+] | 88.9 | 81.9 | 71.2 | 87.7 | 91.7 | 72.9 | 37.6 | 31.3 |
| Sales and marketing | 54.7 | 54.0 | 48.5 | 55.2 | 70.3 | 48.9 | 22.0 | 18.8 |
| General and administrative | 34.2 | 27.9 | 22.7 | 32.5 | 21.3 | 24.0 | 15.6 | 12.5 |
| Research and development | 15.1 | 12.3 | 14.6 | 8.0 | 5.1 | | | |
| Other operating expenses | | 10.8 | | 2.0 | -125.2 | 14.8 | -37.6 | -31.3 |
| EBITDA [+] | 34.2 | 30.8 | 26.8 | 12.5 | 38.3 | 28.4 | 23.0 | 13.1 |
| EBITDA growth | 11.0% | 14.9% | 115.2% | -67.4% | 34.7% | 23.8% | 74.9% | -262.4% |
| EBITDA margin | 21.4% | 19.6% | 19.9% | 9.8% | 24.5% | 21.4% | 27.0% | 18.1% |
| Depreciation | 1.0 | 0.9 | 0.9 | 0.9 | 0.8 | 0.4 | 0.6 | 0.5 |
| EBITA | 33.2 | 29.9 | 26.0 | 11.6 | 37.5 | 28.0 | 22.4 | 12.6 |
| EBITA margin | 20.8% | 19.0% | 19.3% | 9.1% | 24.0% | 21.1% | 26.3% | 17.4% |
| Amortization of intangibles | | | | | 2.6 | 2.5 | | |
| EBIT [+] | 33.2 | 29.9 | 26.0 | 11.6 | 34.8 | 25.5 | 22.4 | 12.6 |
| EBIT growth | 11.1% | 15.1% | 123.8% | -66.6% | 36.7% | 13.7% | 77.8% | -249.3% |
| EBIT margin | 20.8% | 19.0% | 19.3% | 9.1% | 22.3% | 19.2% | 26.3% | 17.4% |
| Non-recurring items [+] | | | | 1.2 | 28.4 | -3.5 | | |
| Asset impairment | | | | | 42.7 | | | |
| Unusual expense | | | | | -15.4 | -3.5 | | |
| Interest income, net [+] | 1.1 | 0.9 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
| Interest expense | | | | | | | | 0.2 |
| Interest income | 1.1 | 0.9 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 |
| Other income (expense), net [+] | -0.2 | -0.5 | 0.2 | 2.7 | -0.2 | -0.2 | 0.8 | 0.0 |
| Change in value of contingent liability | | | | | -15.4 | | | |
| Other | -0.2 | -0.5 | 0.3 | 2.8 | 0.0 | 0.0 | 1.0 | 0.0 |
| Pre-tax income | 34.1 | 30.3 | 26.4 | 13.2 | 6.3 | 28.8 | 23.3 | 12.6 |
| Income taxes | 3.4 | 0.8 | 1.2 | 2.2 | -3.3 | 0.7 | 2.2 | 0.6 |
| Tax rate | 10.0% | 2.7% | 4.4% | 17.0% | | 2.3% | 9.4% | 5.1% |
| Net income | 30.7 | 29.5 | 25.2 | 11.0 | 9.6 | 28.1 | 21.1 | 11.9 |
| Net margin | 19.2% | 18.7% | 18.7% | 8.6% | 6.2% | 21.2% | 24.8% | 16.5% |
| |
| Basic EPS [+] | $0.61 | $0.59 | $0.49 | $0.20 | $0.17 | $0.51 | $0.44 | $0.26 |
| Growth | 3.4% | 20.4% | 140.3% | 20.5% | -66.7% | 15.3% | 70.3% | -244.4% |
| Diluted EPS [+] | $0.58 | $0.56 | $0.48 | $0.20 | $0.16 | $0.49 | $0.43 | $0.25 |
| Growth | 3.5% | 18.0% | 139.7% | 21.3% | -66.4% | 14.9% | 70.6% | -238.9% |
| |
| Shares outstanding (basic) [+] | 50.2 | 49.8 | 51.3 | 53.6 | 56.6 | 55.1 | 47.6 | 45.9 |
| Growth | 0.9% | -2.9% | -4.3% | -5.4% | 2.8% | 15.7% | 3.7% | -0.9% |
| Shares outstanding (diluted) [+] | 52.6 | 52.2 | 52.7 | 54.9 | 58.5 | 57.4 | 49.4 | 47.8 |
| Growth | 0.8% | -1.0% | -4.1% | -6.1% | 1.9% | 16.1% | 3.4% | 3.0% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |